Quality & complianceOfficial

Denmark flags supply problems with Karo Pharma's Centyl with Potassium Chloride tablets

🇩🇰 DKMA · Fri 06 Nov 2026

The Danish Medicines Agency says quality problems have disrupted supply of Centyl med Kaliumklorid 2.5+573 mg coated tablets, with no end date given.

The Danish Medicines Agency (Lægemiddelstyrelsen, DKMA) has published a supply notice for Centyl med Kaliumklorid 2.5+573 mg coated tablets, marketed by Karo Pharma AB. The notice, dated 6 November 2026, reports current problems with supply of the product.

The medicine contains bendroflumethiazide and potassium chloride and carries the ATC code C03AB01. According to the agency, the expected period of disruption runs from the start of November 2026 and is listed as unknown, so no return-to-supply date has been indicated.

DKMA gives the cause as quality problems. It does not say what the problems are, which batches or strengths are affected, or whether any recall or other regulatory action is involved.

The agency directs anyone with questions about the current status to the company itself. The notice appears in DKMA's section for announcements on medicine supply.

What it means for your team

  • Supply and market-access teams with Danish exposure should check the DKMA notice and contact Karo Pharma AB for the latest status, as the agency refers status queries to the company.
  • Quality teams should note that the stated cause is quality problems, but the notice gives no detail on the nature or scope of the issue.
  • With the expected duration given as unknown, contingency planning should not assume a near-term return to normal supply.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →